Ideaya Biosciences announced achievement of first-patient-in in the Phase 1 clinical trial evaluating IDE161 and release of a poster presentation profiling IDE161 at AACR. IDE161 is a potent, selective, small-molecule inhibitor of PARG, a novel and mechanistically-differentiated target in the same clinically validated pathway as poly polymerase.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IDYA:
- TipRanks ‘Perfect 10’ List: 2 Top-Rated Stocks Potentially Undervalued by ~90%
- Ideaya Biosciences initiated with a Buy at Berenberg
- Ideaya Biosciences price target raised to $29 from $26 at Citi
- Ideaya Buy thesis ‘remains intact’ after Q4 report, says Capital One
- Ideaya Biosciences reports Q4 EPS (50c), consensus (56c)
